Sponsored Links
| The Medicines Company Receives European Approval For Angiox(R) (Bivalirudin) For Use In Heart Attack Patients Undergoing Emergency Heart Procedures |
 |
 |
 |
| Medical News - Cardiovascular and Cardiology | |||
|
The Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI)... Read more: Cardiovascular / Cardiology News From Medical News Today
|